The Breast Cancer Surgeon
  • Home
  • About
    • Make An Appointment
    • Curriculum Vitae
    • Honors and Awards
    • Selected Lectures
  • Genetics and Risk factors
    • Genetics and Family History
      • Bermuda Risk Clinic
      • Slide Set for High Risk identification
      • Media
      • Publications
      • Bia in the Reporting of Family History
    • Risk Models and Guidelines
      • FAQ Main Page
      • Simplifying clinical use – genetic risk prediction model BRCAPRO
      • HL7 XML-formatted risk prediction service
      • Risk Clinic Module
    • High Risk Lesions (Atypia/LCIS)
      • Atypical Breast Legions – How high is risk?
  • EHR & CDS
    • Clinical Decision Support for Medical Students
    • The feasibility of using natural language processing to extract clinical information from breast pathology reports
    • Modular EHR
    • Media Video on eCancer TV regarding Electronic Health Records
    • Whats A Matta With EHRs Today
    • Family History Module ASHG
    • Publications EHR
    • HughesRiskApps.Net
      • HughesRiskApps Pedigree Module
      • Breast Surgery Module
  • Breast Cancer/Diseases
    • Breast Cancer and Breast Diseases
    • Breast Cancer Older Women
    • Technique for Axillary Dissection Using the Bookwalter Retractor
  • Blog
Select Page

Of our screening population, what percent are expected to be categorized as “high risk”?

by kshughes | Mar 3, 2016 | Genetic Testing, Guidelines, Lifetime Risk, MRI, Population Level Risk, Tyrer Cuzick

Risk is defined in 2 ways: Risk of mutation (If risk of mutation is 10% or greater consider genetic testing) Risk of breast cancer (If lifetime risk of breast cancer is 20% or greater get an MRI) 4% of your population getting mammography will need genetic testing For...

We run risk models in breast imaging, and we are concerned that all of the patients’ risks are “low”.

by kshughes | Mar 3, 2016 | BRCAPRO, Genetic Testing, Lifetime Risk, Models, MRI, Population Level Risk, Tyrer Cuzick

In a breast imaging population, about 1 in 25 will be eligible for genetic testing. If you are only using BRCAPRO, only 1 in 200 will need an MRI.  Use Tyrer Cuzick 7, and you will see that about 15% will need an MRI....

What percent of a high risk population are expected to be BRCA+?

by kshughes | Mar 3, 2016 | Genetic Testing

If you test a group of patients with a 10% or greater risk of mutation, about 17% will be mutation carriers.  If you test patients based on the NCCN guidelines

The Mammographers have not identified any patients at all that are 20% or greater for lifetime risk.

by kshughes | Mar 3, 2016 | BRCAPRO, Claus, Gail, Genetic Testing, Guidelines, Lifetime Risk, MRI, Population Level Risk, Tyrer Cuzick

If you use Tyrer Cuzick7, about 15% will need an MRI. If you use Claus, about 0.9% will need an MRI. If you use BRCAPRO, about 0.5% will need an MRI. [ASCO_2014_NCCNB_BRCAPRO_TyrerCuzickRiskMutationsLifetimeRisk]

Sometimes risk scores do not appear on the Hughes RiskApps survey summary report- why is this?

by kshughes | Mar 3, 2016 | Genetic Testing, Guidelines, Hughes RiskApps, Hughes RiskApps Express, MRI, Population Level Risk

Although the survey asks patients about their atypia, LCIS status and past genetic test results, the self-reported response is NOT accepted as true until verified by the user. Risk calculations are not run nor presented in the survey summary until the clinician or...

What does the ‘ASO’ mean in “Test Patient (ASO)”?

by kshughes | Mar 3, 2016 | Genetic Testing, Hughes RiskApps, Hughes RiskApps Express

There is no mutation listed in the pedigree, just significance.  Ideally the mutation variant should be entered.  The correct answer is: “Test patient (ASO)” ASO means Allele-Specific Oligonucleotide (ASO), which is the term we used for family specific mutation...

Categories

  • Atypia/LCIS
  • Biopsy
  • Blog
  • Boadicea
  • BRCAPRO
  • Breast Cancer & Breast Disease
  • Breast disease
  • Claus
  • EHR
  • EHR Articles
  • FAQ
  • Gail
  • Genetic Testing
  • Guidelines
  • Hereditary
  • Hereditary cancer
  • Hughes RiskApps
  • Hughes RiskApps Express
  • Lifetime Risk
  • Models
  • MRI
  • Myriad
  • Ovarian Cancer
  • Population Level Risk
  • Race/Ethnicity
  • Surgery
  • Tyrer Cuzick

Archives

  • July 2016
  • May 2016
  • March 2016
  • February 2016
  • March 2014
  • December 2013
  • July 2013
  • July 2012
  • June 2012
  • March 2012

Recent Posts

  • Knowledge bases for Genetics and Risk Assessment
  • Genetic Panel Testing: Incidental Findings and Actionable Mutations
  • Should a Core Biopsy be counted in the Gail model?
  • VIDEO: Treat most older women with stage I breast cancer with lumpectomy only
  • Patients with a strong family history and ones with no family history can sometimes have the same risk. Why?
  • Facebook
  • RSS

Designed by Begin Bound, LLC